Compare Adaptive Biotechnologies Corp (ADPT) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Ryanair Holdings plc — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while Ryanair Holdings plc trades at $60.03 (market cap $29.63B). The key difference: Ryanair Holdings plc is far larger — about 7.3× Adaptive Biotechnologies Corp's market cap, and Ryanair Holdings plc pays a 1.51% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | RYAAY | |
|---|---|---|
Market Cap | $4.04B | $29.63B |
Sector | Health | Industrials |
52-Week High | $25.45 | $73.82 |
52-Week Low | $12.30 | $53.24 |
Enterprise Value | $4.10B | $26.61B |
Dividend Yield | — | 1.51% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
